BCAXBicara Therapeutics Inc.

$17.04-8.8% 1Y

What is the market doing?

Watch

The market is leaning against it: in a downtrend (−19% vs 200-day) and a crowded short (+16% of shares).

2 to watch, 1 neutral
TrendDowntrendderived · Oct 23, 2026

In a downtrend, below its 50- and 200-day averages. Price is −19% vs its 200-day average.

Insider conviction−$1.6M (90 days to Oct 22, 2026)SEC EDGAR · Oct 22, 2026

Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).

Short interest16% of sharesFINRA · Sep 30, 2026

A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

1-year returnbehind 73% of the market
vs 200-day avgbehind 84% of the market

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How BCAX is trading

Bicara Therapeutics Inc. is −8.8% over the past year while the S&P 500 is +16%: 25 points behind the market.

−8.8%

1-year return · S&P 500 +16%

vs 200-day average
−19%

vs 200-day average · a clear downtrend

RSI (14)
48

RSI (14) · neutral

Below its 52-week high
44%

Below its 52-week high

Oct 15, 2024$8.71 – $30.39 · dashed line: 200-day averageOct 23, 2026
Details›
Last close2026-10-23
$17.04
1 monthS&P 500 −0.94%
−14%
1 yearS&P 500 +16%
−8.8%
vs 50-day average$20.94
−19%
52-week high
$30.39
52-week low
$13.93
Annualised volatility
74%
Calendar-year price return
YearReturn
2026 (year to date)+1.2%
2025−3.4%
Average return by calendar month, 2024–2026
MonthYearsPositiveAverage
Jan20 of 2−14%
Feb21 of 2+2.6%
Mar21 of 2+8.3%
Apr22 of 2+9.4%
May21 of 2−17%
Jun22 of 2+18%
Jul21 of 2+5.0%
Aug21 of 2−3.2%
Sep21 of 2+6.3%
Oct31 of 3−4.2%
Nov21 of 2+1.0%
Dec20 of 2−13%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.

Where the price stands

Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.

What it has returned

With dividends, year by year, month by month, and by calendar month on average.

On our screens:Most shorted stocks